Clinical trials: sponsored by SWOG Cancer Research Network
Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment
This phase II trial tests how well adding revumenib to usual treatment (blinatumomab) compared to usual treatment alone works in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) or acute leukemia with ambiguous…
- Conditions
- Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
- Trial name
- NCT07636564
- Testing
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration
- Volunteers
- 90 people
- Sponsor
- SWOG Cancer Research Network
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to…
- Trial name
- NCT06031688
- Testing
- Biospecimen Collection, Computed Tomography, Lymphoscintigraphy
- Where
- 278 sites in United States
- Volunteers
- 56 people
- Sponsor
- SWOG Cancer Research Network
Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
This phase I/II trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed)…
- Conditions
- Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia, Refractory T Lymphoblastic Lymphoma, T Lymphoblastic Lymphoma
- Trial name
- NCT04315324
- Testing
- AKR1C3-activated Prodrug AST-3424, Biopsy Procedure, Biospecimen Collection
- Where
- 163 sites in United States
- Volunteers
- 67 people
- Sponsor
- SWOG Cancer Research Network
Plasma Cell Myeloma
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and…
- Trial name
- NCT05561387
- Testing
- Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone
- Where
- 397 sites in United States
- Volunteers
- 510 people
- Sponsor
- SWOG Cancer Research Network
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
This phase II/III Lung-MAP trial studies how well immunotherapy treatment with N-803 (ALT-803) and pembrolizumab working in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced).
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT05096663
- Testing
- Cobalamin, Dexamethasone, Docetaxel
- Where
- 350 sites in United States
- Volunteers
- 82 people
- Sponsor
- SWOG Cancer Research Network
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
This randomized phase II/III trial studies how well afatinib dimaleate with cetuximab works and compares it with afatinib dimaleate alone in treating patients with newly diagnosed stage IV or recurrent (has come back), epidermal…
- Trial name
- NCT02438722
- Testing
- Afatinib Dimaleate, Cetuximab, Laboratory Biomarker Analysis
- Where
- 638 sites in United States
- Volunteers
- 174 people
- Sponsor
- SWOG Cancer Research Network
Atypical Hyperplasia of the Breast, Lobular Breast Carcinoma In Situ
Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)
This trial studies the implementation of web-based decision support tools for patients with atypical hyperplasia or lobular carcinoma in situ and healthcare providers.
- Conditions
- Atypical Hyperplasia of the Breast, Lobular Breast Carcinoma In Situ, Pleomorphic Lobular Breast Carcinoma In Situ
- Trial name
- NCT04496739
- Testing
- Cancer Educational Materials, Decision Aid, Interview
- Where
- 97 sites in United States, Guam
- Volunteers
- 412 people, healthy volunteers welcome
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
Letrozole After Tamoxifen in Treating Women With Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen.
- Trial name
- NCT00003140
- Testing
- letrozole
- Where
- 57 sites in Canada, United Kingdom
- Volunteers
- 5,187 people
- Sponsor
- NCIC Clinical Trials Group
Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating…
- Conditions
- Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
- Trial name
- NCT03091660
- Testing
- BCG Solution, BCG Tokyo-172 Strain Solution, BCG Tokyo-172 Strain Vaccine
- Where
- 174 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- SWOG Cancer Research Network
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
This phase II LUNG-MAP treatment trial studies how well selpercatinib works in treating patients with RET fusion-positive non-small cell lung cancer that is stage IV or has come back (recurrent).
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Trial name
- NCT04268550
- Testing
- Selpercatinib
- Where
- 306 sites in United States
- Volunteers
- 124 people
- Sponsor
- SWOG Cancer Research Network
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back.
- Conditions
- Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma
- Trial name
- NCT03845296
- Testing
- Rucaparib
- Where
- 950 sites in United States
- Volunteers
- 64 people
- Sponsor
- SWOG Cancer Research Network
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)
This phase II LUNG-MAP treatment trial studies how well combination treatment (talazoparib plus avelumab) works in treating patients with non-squamous non-small cell lung cancer that has an STK11 gene mutation and has come back…
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- NCT04173507
- Testing
- Avelumab, Talazoparib, Talazoparib Tosylate
- Where
- 325 sites in United States
- Volunteers
- 47 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00754845
- Testing
- letrozole
- Where
- 43 sites in Canada, United Kingdom
- Volunteers
- 1,918 people
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer
Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Radiation to the tumor site and surrounding area may kill more tumor cells.
- Trial name
- NCT00005957
- Testing
- Standard Breast Irradiation, Breast Radiation plus Regional Radiation
- Where
- 26 sites in Canada
- Volunteers
- 1,832 people
- Sponsor
- NCIC Clinical Trials Group
Sarcoma
Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006734
- Testing
- filgrastim, cyclophosphamide, doxorubicin hydrochloride
- Where
- 239 sites in United States, Australia and 5 more
- Volunteers
- 587 people
- Sponsor
- Children's Oncology Group
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
This phase II trial studies how well durvalumab and tremelimumab works in treating patients with stage IV lung cancer that has come back after previous treatment.
- Trial name
- NCT03373760
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Tremelimumab
- Where
- 1,021 sites in United States
- Volunteers
- 67 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer, Musculoskeletal Complications
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy
RATIONALE: Duloxetine hydrochloride may lessen muscle, bone, and joint pain caused by hormone therapy. It is not yet known whether duloxetine hydrochloride is more effective than a placebo in treating patients with muscle, bone…
- Conditions
- Breast Cancer, Musculoskeletal Complications, Pain
- Trial name
- NCT01598298
- Testing
- duloxetine hydrochloride
- Where
- 714 sites in United States
- Volunteers
- 299 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00002874
- Testing
- bicalutamide, radiation therapy
- Where
- 240 sites in United States, Canada
- Volunteers
- 840 people
- Sponsor
- Radiation Therapy Oncology Group
ATM Gene Mutation, ATR Gene Mutation
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
This phase II trial studies how well talazoparib works in treating patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer that has come back after previous treatment.
- Conditions
- ATM Gene Mutation, ATR Gene Mutation, BARD1 Gene Mutation, BRCA1 Gene Mutation
- Trial name
- NCT03377556
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- Where
- 1,157 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00003653
- Testing
- bicalutamide, buserelin, cyproterone acetate
- Where
- 29 sites in Canada
- Volunteers
- 1,386 people
- Sponsor
- NCIC Clinical Trials Group